beta-amyloid (Abeta)42(43), abeta42, abeta40 and apoE immunostaining of plaques in fatal head injury.
beta-Amyloid (Abeta) deposits are found in the brains of approximately one-third of patients who die within days after a severe head injury; their presence correlating strongly with possession of an apolipoprotein E (apoE)-epsilon4 allele. The aim of the study was to investigate the relationship between Abeta42, Abeta40 and apoE immunostaining of Abeta plaques in the cerebral cortex and the relevance of apoE genotype in 23 fatally head-injured patients. These cases were known to have Abeta deposits from a previous study in which they were examined and semiquantified and related to apoE genotype. In the present study, the temporal cortex was probed using four different antibodies that recognize Abeta42(43), Abeta40 and an antibody to apoE. Abeta42(43)-positive plaques were observed in all of the 23 cases and Abeta40 immunoreactivity in only 11 of the 23 cases. In addition, semiquantitative analysis showed that relatively fewer plaques were detected with anti-Abeta40 than anti-Abeta42(43). ApoE-immunoreactive plaques were identified in 18 of the 23 cases. The number of plaques stained for apoE was relatively less than for Abeta42(43) but greater than for Abeta40. Furthermore, the density of Abeta plaques detected using either Abeta42(43), Abeta40 or apoE antibodies was associated with possession of apoE-epsilon4 in an allele dose-dependent manner. The results are consistent with Abeta42(43) as the initially deposited species in brain parenchyma and provide evidence that apoE is involved in the early stages of amyloid deposition. Further, the findings may be of relevance to the role of apoE genotype in influencing outcome after acute brain injury.
Horsburgh
K
K
Wellcome Surgical Institute and Hugh Fraser Neuroscience Laboratories, University of Glasgow, Glasgow, UK. kh5j@udcf.gla.ac.uk
Cole
G M
GM
Yang
F
F
Savage
M J
MJ
Greenberg
B D
BD
Gentleman
S M
SM
Graham
D I
DI
Nicoll
J A
JA
D000293:Adolescent; D000328:Adult; D000368:Aged; D000544:Alzheimer Disease / Q000235:genetics / Q000473:pathology; D016229:Amyloid beta-Peptides / Q000032:analysis* / Q000276:immunology; D000911:Antibodies, Monoclonal; D001057:Apolipoproteins E / Q000032:analysis* / Q000235:genetics / Q000276:immunology; D001921:Brain / Q000473:pathology*; D001923:Brain Chemistry; D006259:Craniocerebral Trauma / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D005838:Genotype; D006801:Humans; D008875:Middle Aged; D010446:Peptide Fragments / Q000032:analysis* / Q000276:immunology; D058225:Plaque, Amyloid / Q000737:chemistry / Q000473:pathology; D016622:Silver Staining
D016229:Amyloid beta-Peptides; D000911:Antibodies, Monoclonal; D001057:Apolipoproteins E; D010446:Peptide Fragments; C078592:amyloid beta-protein (1-40); C075222:amyloid beta-protein (1-42); C098994:amyloid beta-protein (1-43)